for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aerie Pharmaceuticals Inc

AERI.OQ

Latest Trade

6.73USD

Change

-0.38(-5.34%)

Volume

324,263

Today's Range

6.70

 - 

7.21

52 Week Range

6.67

 - 

21.24

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.11
Open
7.03
Volume
324,263
3M AVG Volume
23.49
Today's High
7.21
Today's Low
6.70
52 Week High
21.24
52 Week Low
6.67
Shares Out (MIL)
47.36
Market Cap (MIL)
336.71
Forward P/E
-2.56
Dividend (Yield %)
--

Next Event

Q4 2021 Aerie Pharmaceuticals Inc Earnings Release

Latest Developments

More

Aerie Pharma Interim CFO And VP Of Finance Christopher Staten Provided Notice Of Resignation

Aerie Pharma Announces Positive Phase 3 Results For Netarsudil Ophthalmic Solution 0.02%

Aerie Pharmaceuticals Chairman & CEO Vicente Steps Down; Co Names Benjamin McGraw Interim Executive Chair

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aerie Pharmaceuticals Inc

Aerie Pharmaceuticals, Inc. is an ophthalmic pharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. The Company’s commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa is under preclinical and clinical trials. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma. Rocklatan is under preclinical and clinical trials to be effective in reducing IOP.

Industry

Biotechnology & Drugs

Contact Info

4301 Emperor Blvd Ste 400

DURHAM, NC

27703-7615

United States

+1.919.2375300

http://www.aeriepharma.com/

Executive Leadership

Benjamin F. Mcgraw

Interim Executive Chairman of the Board

Thomas A. Mitro

President, Chief Operating Officer

Raj Kannan

Chief Executive Officer, Director

Casey C. Kopczynski

Co-Founder, Chief Scientific Officer

John W. Larocca

General Counsel and Assistant Secretary

Key Stats

2.00 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.1K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

-4.650

2019

-3.400

2020

-3.120

2021(E)

-2.786
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.23
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-65.07
Return on Equity (TTM)
-46.34

Latest News

Latest News

BRIEF-Aerie Pharmaceuticals Says Board Approved Increase In Size Of Board To Nine Members From Eight

* AERIE PHARMACEUTICALS INC - ON JUNE 9, BOARD APPROVED AN INCREASE IN SIZE OF BOARD FROM EIGHT MEMBERS TO NINE MEMBERS Source text: (https://bit.ly/37hZ2Yi) Further company coverage:

BRIEF-Aerie Pharma Appoints Peter Mcdonnell To The Board

* AERIE PHARMACEUTICALS APPOINTS PETER J. MCDONNELL, M.D., TO THE COMPANY’S BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Aerie Pharmaceuticals Says Withdrawing 2020 Guidance For Net Revenues And Net Cash Used In Operations

* AERIE PHARMACEUTICALS PROVIDES 2020 COMPANY AND GUIDANCE UPDATE ASSOCIATED WITH COVID-19

BRIEF-James Flynn Reports 5.45% Passive Stake In Aerie Pharmaceuticals

* JAMES FLYNN REPORTS 5.45% PASSIVE STAKE IN AERIE PHARMACEUTICALS INC AS OF MARCH 13 - SEC FILING Source text (https://bit.ly/3dq2MJP)

BRIEF-Aerie Pharmaceuticals Expects FY 2020 Revenue Between $100 Million And $110 Million

* AERIE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS, PROVIDES 2020 GUIDANCE AND BUSINESS UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up